Clinical trials for Penile cancer and germ cell tumors

41 currently recruiting clinical trials
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Germ cell tumor None Systemic Treatment-Naive Systemic Treatment-Naive Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Locally Advanced Metastatic MET 1 2 3 or more
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Penile cancer and germ cell tumors #NCT05529251 #2024-514636-25-00
Germ cell tumor Pure seminoma Locally Advanced None Systemic Treatment-Naive Testis Good prognosis
Surgery Radiotherapy Chemotherapy Radiotherapy
11 recruiting sites
Centre Léon Bérard
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00
Groupe 6
Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00
Groupe 5
Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05592626 #2023-505334-10-00
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Marengo Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Phase 2 autres tumeurs solides
Locally Advanced Metastatic Metastatic Castration-resistant TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc